Economic Burden of Multiple Myeloma: Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Author Information
Author(s): Keesari Praneeth Reddy, Diana Samuels, Charan Thej Reddy Vegivinti, Yashwitha Sai Pulakurthi, Revathi Kudithi, Meekoo Dhar, Janakiram Murali
Hypothesis
Understanding the economic burden and cost-effectiveness of therapies for multiple myeloma is crucial for clinicians and researchers.
Conclusion
Using more effective therapies like CAR-T earlier may be more cost-effective depending on the country and model used.
Supporting Evidence
- Multiple myeloma has a high economic burden, with costs ranging from $20,000 to $40,000 per patient per month.
- CAR-T therapy has shown improved survival rates in patients with triple-class refractory multiple myeloma.
- Effective regimens used early in treatment can lower overall costs during the disease course.
Takeaway
This study looks at how much it costs to treat multiple myeloma and finds that some new treatments might save money if used early.
Methodology
The review analyzes cost-effectiveness studies and compares costs associated with different treatment regimens for multiple myeloma.
Limitations
The study lacks long-term clinical data for bispecific antibodies and does not account for indirect costs in many analyses.
Participant Demographics
The study includes patients with multiple myeloma, with a focus on those exposed to multiple classes of drugs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website